
Anat Epstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9225578/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ATRT-04. Clinical and (epi)genetic characterisation of patients with atypical teratoid/rhabdoid tumor (ATRT) and extracranial malignant rhabdoid tumor conceived following assisted reproduction technologies (ART). Neuro-Oncology, 2022, 24, i2-i2.	0.6	0
2	Phase 1 clinical trial of durvalumab in children with solid and central nervous system tumors Journal of Clinical Oncology, 2022, 40, 10029-10029.	0.8	1
3	Maximizing the potential of aggressive mouse tumor models in preclinical drug testing. Scientific Reports, 2021, 11, 11580.	1.6	2
4	Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults. Neuro-Oncology Advances, 2021, 3, vdab037.	0.4	3
5	Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers. Frontiers in Oncology, 2020, 10, 563156.	1.3	9
6	<scp>SMARCB1</scp> loss induces druggable cyclin <scp>D1</scp> deficiency via upregulation of <scp><i>MIR17HG</i></scp> in atypical teratoid rhabdoid tumors. Journal of Pathology, 2020, 252, 77-87.	2.1	11
7	Abstract 462: The mutated chromatin modifier gene, H3F3AK27M, is a druggable target of DNA hypomethylating agents in pediatric high-grade glioma. , 2020, , .		0
8	GRK2 promotes growth of medulloblastoma cells and protects them from chemotherapy-induced apoptosis. Scientific Reports, 2019, 9, 13902.	1.6	9
9	Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma. PLoS ONE, 2019, 14, e0206394.	1.1	4
10	CSIG-29. STRUCTURAL AND FUNCTIONAL STUDIES OF PID1, A NOVEL GROWTH SUPPRESSOR IN BRAIN TUMORS. Neuro-Oncology, 2019, 21, vi50-vi50.	0.6	0
11	Rare Pediatric Invasive Gliofibroma Has BRAFV600E Mutation and Transiently Responds to Targeted Therapy Before Progressive Clonal Evolution. JCO Precision Oncology, 2019, 3, 1-10.	1.5	2
12	THER-05. CONTINUOUS AND BOLUS INTRAVENTRICULAR TOPOTECAN PROLONG SURVIVAL IN A MOUSE MODEL OF LEPTOMENINGEAL MEDULLOBLASTOMA. Neuro-Oncology, 2019, 21, ii115-ii115.	0.6	0
13	<scp>WTâ€CLS1</scp> is a rhabdoid tumor cell line and can be inhibited by <scp>miR</scp> â€16. Cancer Reports, 2019, 2, .	0.6	3
14	CBMT-36. GRK2 PROMOTES MEDULLOBLASTOMA GROWTH AND SURVIVAL. Neuro-Oncology, 2018, 20, vi40-vi40.	0.6	0
15	PID1 increases chemotherapy-induced apoptosis in medulloblastoma and glioblastoma cells in a manner that involves NFIºB. Scientific Reports, 2017, 7, 835.	1.6	5
16	Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget, 2017, 8, 52193-52210.	0.8	24
17	BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma. PLoS ONE, 2016, 11, e0156907.	1.1	7
18	Re-irradiation of Recurrent Pineal Germ Cell Tumors with Radiosurgery: Report of Two Cases and Review of Literature. Cureus, 2016, 8, e585.	0.2	13

ANAT EPSTEIN

#	Article	IF	CITATIONS
19	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	7.7	191
20	Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. Neuro-Oncology, 2016, 18, 126-131.	0.6	69
21	CXCR4 increases <i>in-vivo</i> glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study. Oncotarget, 2016, 7, 83701-83719.	0.8	75
22	Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia. Frontiers in Oncology, 2015, 5, 191.	1.3	16
23	Pediatric Brain Tumor Cell Lines. Journal of Cellular Biochemistry, 2015, 116, 218-224.	1.2	50
24	The Chromatin-Modifying Protein HMGA2 Promotes Atypical Teratoid/Rhabdoid Cell Tumorigenicity. Journal of Neuropathology and Experimental Neurology, 2015, 74, 177-185.	0.9	26
25	Wnt pathway in atypical teratoid rhabdoid tumors. Neuro-Oncology, 2015, 17, 526-535.	0.6	21
26	Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas. Clinical Cancer Research, 2015, 21, 1457-1465.	3.2	92
27	Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget, 2015, 6, 3165-3177.	0.8	66
28	PID1 IS A NOVEL SENSITIZER OF BRAIN TUMOR CELLS TO CHEMOTHERAPY. Neuro-Oncology, 2014, 16, iii26-iii26.	0.6	1
29	<i>PID1</i> (<i>NYGGF4</i>), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas. Clinical Cancer Research, 2014, 20, 827-836.	3.2	29
30	A retrospective analysis of recurrent intracranial ependymoma. Pediatric Blood and Cancer, 2014, 61, 1195-1201.	0.8	39
31	A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1. Neuro-Oncology, 2014, 16, 191-203.	0.6	47
32	Novel Paracrine Modulation of Notch–DLL4 Signaling by Fibulin-3 Promotes Angiogenesis in High-Grade Gliomas. Cancer Research, 2014, 74, 5435-5448.	0.4	39
33	Heparanase-Induced GEF-H1 Signaling Regulates the Cytoskeletal Dynamics of Brain Metastatic Breast Cancer Cells. Molecular Cancer Research, 2012, 10, 689-702.	1.5	37
34	Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature. BMC Medical Genetics, 2012, 13, 19.	2.1	37
35	c-Abl Is an Upstream Regulator of Acid Sphingomyelinase in Apoptosis Induced by Inhibition of Integrins $\hat{1}\pm v\hat{1}^23$ and $\hat{1}\pm v\hat{1}^25$. PLoS ONE, 2012, 7, e42291.	1.1	4
36	Choroid plexus tumors; management, outcome, and association with the Li–Fraumeni syndrome: The Children's Hospital Los Angeles (CHLA) experience, 1991–2010. Pediatric Blood and Cancer, 2012, 58, 905-909.	0.8	72

ANAT EPSTEIN

#	Article	IF	CITATIONS
37	Novel cell lines established from pediatric brain tumors. Journal of Neuro-Oncology, 2012, 107, 269-280.	1.4	38
38	Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. Journal of Neuro-Oncology, 2011, 103, 673-680.	1.4	44
39	Gliovascular and cytokine interactions modulate brain endothelial barrier in vitro. Journal of Neuroinflammation, 2011, 8, 162.	3.1	32
40	Novel cancer vaccine based on genes of <i>Salmonella</i> pathogenicity island 2. International Journal of Cancer, 2010, 126, 2622-2634.	2.3	80
41	c-Abl mediates endothelial apoptosis induced by inhibition of integrins αvβ3 and αvβ5 and by disruption of actin. Blood, 2010, 115, 2709-2718.	0.6	25
42	Nuclear factor IA is expressed in astrocytomas and is associated with improved survival. Neuro-Oncology, 2010, 12, 122-132.	0.6	36
43	Highâ€dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Cancer, 2009, 115, 2956-2963.	2.0	40
44	Metabolism of Orthotopic Mouse Brain Tumor Models. Molecular Imaging, 2009, 8, 7290.2009.00019.	0.7	10
45	PROGRESS IN THE TREATMENT OF CHILDHOOD BRAIN TUMORS: No Room for Complacency. Pediatric Hematology and Oncology, 2007, 24, 79-84.	0.3	9
46	Inducing a mode of NK-resistance to suppression by stress and surgery: A potential approach based on low dose of poly l–C to reduce postoperative cancer metastasis. Brain, Behavior, and Immunity, 2007, 21, 395-408.	2.0	25
47	Androgen inducibility ofFgf8 in Shionogi carcinoma 115 cells correlates with an adjacent t(5;19) translocation. Genes Chromosomes and Cancer, 2006, 45, 169-181.	1.5	5
48	Endothelial apoptosis induced by inhibition of integrins αvβ3 and αvβ5 involves ceramide metabolic pathways. Blood, 2005, 105, 4353-4361.	0.6	59
49	Bone Marrow Mesenchymal Stem Cells Provide an Alternate Pathway of Osteoclast Activation and Bone Destruction by Cancer Cells. Cancer Research, 2005, 65, 1129-1135.	0.4	73
50	Approaches to Treatment for Extraocular Retinoblastoma. Journal of Pediatric Hematology/Oncology, 2004, 26, 31-34.	0.3	76
51	Induction of Intercellular Adhesion Molecule-1 on Human Brain Endothelial Cells by HIV-1 gp120: Role of CD4 and Chemokine Coreceptors. Laboratory Investigation, 2003, 83, 1787-1798.	1.7	32
52	Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood, 2003, 102, 1506-1514.	0.6	141
53	Ceramide Signaling in Fenretinide-induced Endothelial Cell Apoptosis. Journal of Biological Chemistry, 2002, 277, 49531-49537.	1.6	74
54	Successful Multimodality Therapy of Recurrent Multifocal Juvenile Granulosa Cell Tumor of the Ovary. Journal of Pediatric Hematology/Oncology, 2002, 24, 229-233.	0.3	20

ANAT EPSTEIN

#	Article	IF	CITATIONS
55	Cbl functions downstream of Src kinases in FCγRI signaling in primary human macrophages. Journal of Leukocyte Biology, 1999, 65, 523-534.	1.5	22
56	Characterization of Cbl-Nck and Nck-Pak1 Interactions in Myeloid FcÎ ³ RII Signaling. Experimental Cell Research, 1998, 245, 330-342.	1.2	27
57	Differential Expression of Wnt Genes in Normal and Flat Variants of PC 12 Cells, a Cell Line Responsive to Ectopic Wnt1 Expression. Growth Factors, 1998, 15, 149-158.	0.5	9
58	Protein Tyrosine Phosphatase Inhibitors in FcγRI-Induced Myeloid Oxidant Signaling. Experimental Cell Research, 1997, 237, 288-295.	1.2	12